Hillstream Biopharma (NASDAQ:CNTN) Cut to “Strong Sell” at Wall Street Zen

Hillstream Biopharma (NASDAQ:CNTN – Get Free Report) was downgraded by analysts at Wall Street Zen from a “sell” rating to a “strong sell” rating in a report released on Sunday, Wall Street Zen reports.

Separately, Weiss Ratings cut shares of Hillstream Biopharma from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, November 12th. One equities research analyst has rated the stock with a Sell rating. Based on data from MarketBeat.com, Hillstream Biopharma has a consensus rating of “Sell”.

Read Our Latest Research Report on Hillstream Biopharma

Hillstream Biopharma Trading Down 1.6%

Shares of NASDAQ CNTN opened at $1.21 on Friday. The firm’s 50-day moving average price is $2.00 and its 200-day moving average price is $2.59. Hillstream Biopharma has a 1-year low of $1.19 and a 1-year high of $5.83.

Hillstream Biopharma (NASDAQ:CNTN – Get Free Report) last posted its quarterly earnings results on Monday, November 16th. The company reported ($0.16) earnings per share (EPS) for the quarter. The firm had revenue of $3.05 million for the quarter.

About Hillstream Biopharma

(Get Free Report)

Hillstream BioPharma is a biotechnology company focused on developing experimental treatments for cancer, particularly drug-resistant tumors and cancer stem cells. Its research centers on ferroptosis, a form of cell death that may offer a way to attack cancer cells that are difficult to treat with existing therapies. The company’s development work includes its LION platform, which uses liposomal iron oxide nanoparticles to deliver iron to cancer cells and promote ferroptosis. Hillstream has described HSB-1216 as a potential cancer treatment based on this approach.

See Also

Receive News & Ratings for Hillstream Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hillstream Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.